Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc.

Bullboard Posts

Comment by 294everon Jun 21, 2020 1:18am

172 Views

Post# 31173877

RE:RE:RE:Friday was the first dead cat bounce here

Before I actually hit the ignore button I thought I'd do some DD of my own

@synergy from CEO.CA speaking of recycling...same old spew you're pulling over there. The pot calling the kettle black if I've ever heard it

BTW that so called Oxford drug has been around since Christ was a pup
Do your due diligence please and don't spout negativity for the sake of hearing oneself

officially ignored sir best of luck!

Bullboard Posts

Advancing flagship Ishkõday Gold Project in Ontario